News | November 07, 2022
Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Jamnagar’s contributions towards wellness will get a global identity with WHO’s Global Centre for Traditional Medicine
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The company performed particularly well in operational eco-efficiency, environmental and social reporting
Company working on COVID vaccine INO 4800
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Subscribe To Our Newsletter & Stay Updated
